As previously reported, Raymond James downgraded INmune Bio (INMB) to Market Perform from Outperform and removed the firm’s prior $23 price target after XPro Phase 2 data in early Alzheimer’s disease “missed the mark.” An effect size was shown in a subset of patients with greater neuroinflammation, but the study did not hit the primary endpoint and the firm sees greater risk to this “key program” moving forward, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- INmune Bio reports findings from Phase 2 MINDFuL trial of XPro
- Biotech INmune BIO (INMB) Collapses 60% after Alzheimer’s Trial Misses Goals
- INmune Bio reports primary endpoint of MINDFuL study not met
- INmune Bio down 52% after primary endpoint of MINDFuL study not met